Programmed Co-delivery of tamoxifen and docetaxel using lipid-coated mesoporous silica nanoparticles for overcoming CYP3A4-mediated resistance in triple-negative breast cancer treatment

• Published in: Biomedicine & pharmacotherapy Vol. 170; p. 116084
• Main Authors: Wang, Yinan, Cheng, WeiYi, Zhu, Jingjing, He, Li, Ren, WeiYe, Bao, Dandan, Piao, Ji-Gang
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.01.2024; Elsevier
• Subjects: Docetaxel; Drug combination; Lipid-coated mesoporous silica nanoparticles; Tamoxifen; Triple-negative breast cancer; Drug combination; Lipid-coated mesoporous silica nanoparticles; Tamoxifen; Docetaxel; Triple-negative breast cancer
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.116084

This study aims to revolutionize the treatment of aggressive triple-negative breast cancer (TNBC), notorious for its resistance to standard therapies. By ingeniously combining Tamoxifen (TMX) and Docetaxel (DTX) within a lipid-coated mesoporous silica nanoparticle (LP-MSN) delivery system, we intend to enhance therapeutic efficacy while circumventing DTX resistance mediated by CYP3A4 expression. We rigorously tested TNBC cell lines to confirm the responsiveness to Docetaxel (DTX) and Tamoxifen (TMX). We adeptly engineered LP-MSN nanoparticles and conducted a thorough examination of the optimal drug release strategy, evaluating the LP-MSN system's ability to mitigate the impact of CYP3A4 on DTX. Additionally, we comprehensively analyzed its pharmacological performance. Our innovative approach utilizing TMX and DTX within LP-MSN showcased remarkable efficacy. Sequential drug release from the lipid layer and mesoporous core curbed CYP3A4-mediated metabolism, substantially enhancing cytotoxic effects on TNBC cells without harming normal cells. This pioneering research introduces a breakthrough strategy for tackling TNBC. By capitalizing on synergistic TMX and DTX effects via LP-MSN, we surmount drug resistance mediated by CYP3A4. This advancement holds immense potential for transforming TNBC treatment, warranting further clinical validation. [Display omitted] •Overcoming DTX Resistance in TNBC: Addressing the challenge of docetaxel (DTX)-induced resistance in triple-negative breast cancer (TNBC) by exploring innovative strategies to enhance its therapeutic efficacy.•Synergistic Combination Therapy: Proposing a synergistic combination therapy involving tamoxifen (TMX) to enhance the efficacy of DTX and overcome multidrug resistance, offering a promising strategy for TNBC treatment.•Tailored Drug Delivery Strategy: Presenting a structured drug delivery approach using LP-MSN, which enables spatial separation of drugs, sequential administration, and improved patient compliance for enhanced therapeutic outcomes.